Latest News for: sionna

Edit

Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference

Enid News & Eagle 09 Oct 2026
Previously disclosed post hoc PreciSION CF analyses of SION-719 support advancement of SION-451 + SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial ... .
Edit

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna

Enid News & Eagle 07 Oct 2026
(“Sionna” or the “Company”) (NASDAQ.
Edit

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. ...

Nasdaq Globe Newswire 07 Oct 2026
(“Sionna” or the “Company”) (NASDAQ.
Edit

Statement of Changes in Beneficial Ownership (Form 4) (Sionna Therapeutics Inc)

Public Technologies 22 Sep 2026
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) ... See Instruction 10. UNITED STATES SECURITIES AND EXCHANGE COMMISSION ... OMB Number ... Sionna Therapeutics, Inc ... Sionna Therapeutics Inc.
Edit

Notice of Proposed Sale of Securities (Form 144) (Sionna Therapeutics Inc)

Public Technologies 17 Sep 2026
). The text version of this document is not available ... Sionna Therapeutics Inc.
Edit

Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial (Form 8-K) (Sionna Therapeutics Inc)

Public Technologies 14 Sep 2026
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination ... Sionna to host conference call today at 4.30 p.m ... 14, 2026 (GLOBE NEWSWIRE) - Sionna Therapeutics, Inc ... Sionna Therapeutics' live webcast will begin at 4.30 p.m.
  • 1

Article Search

tools
×
×
×
×